These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36693765)

  • 1. Preparation and performance of latanoprost-loaded hydrogels as a lacrimal suppository for the treatment of glaucoma.
    Xiao S; Ma A; Ma Y; Bai H; Zhang B; Li J; Zhou H
    J Biomater Appl; 2023 Apr; 37(9):1529-1541. PubMed ID: 36693765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma.
    Zhao J; Xiong J; Ning Y; Zhao J; Wang Z; Long L; He H; Gou J; Yin T; Tang X; Zhang Y
    Eur J Pharm Biopharm; 2023 Apr; 185():44-54. PubMed ID: 36841507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension.
    Cheng YH; Hung KH; Tsai TH; Lee CJ; Ku RY; Chiu AW; Chiou SH; Liu CJ
    Acta Biomater; 2014 Oct; 10(10):4360-6. PubMed ID: 24914827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.
    Ciolino JB; Stefanescu CF; Ross AE; Salvador-Culla B; Cortez P; Ford EM; Wymbs KA; Sprague SL; Mascoop DR; Rudina SS; Trauger SA; Cade F; Kohane DS
    Biomaterials; 2014 Jan; 35(1):432-9. PubMed ID: 24094935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment.
    Cheng YH; Ko YC; Chang YF; Huang SH; Liu CJ
    Exp Eye Res; 2019 Feb; 179():179-187. PubMed ID: 30471279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment.
    Cheng YH; Tsai TH; Jhan YY; Chiu AW; Tsai KL; Chien CS; Chiou SH; Liu CJ
    Carbohydr Polym; 2016 Jun; 144():390-9. PubMed ID: 27083831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment.
    Guo X; Zhang J; Liu X; Lu Y; Shi Y; Li X; Wang S; Huang J; Liu H; Zhou H; Li Q; Luo L; You J
    J Control Release; 2023 Sep; 361():534-546. PubMed ID: 37567509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroprotective properties of latanoprost].
    Kurysheva NI
    Vestn Oftalmol; 2022; 138(4):126-134. PubMed ID: 36004601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy.
    Shin DH; McCracken MS; Bendel RE; Pearlman R; Juzych MS; Hughes BA; Schulz LL; Kim C; Baek NH
    Ophthalmology; 1999 Feb; 106(2):386-90. PubMed ID: 9951495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo.
    Sehi M; Grewal DS; Feuer WJ; Greenfield DS
    Vision Res; 2011 Jan; 51(2):235-42. PubMed ID: 20813123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of replacement of timolol-pilocarpine with latanoprost in pseudoexfoliation glaucoma.
    Bojić L; Mandić Z; Novak-Laus K; Sonicki Z; Karelović D
    Coll Antropol; 2003 Dec; 27(2):729-34. PubMed ID: 14746165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB; Ross AE; Tulsan R; Watts AC; Wang RF; Zurakowski D; Serle JB; Kohane DS
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma.
    Chen L; Wu R
    Acta Biochim Pol; 2022 May; 69(2):423-428. PubMed ID: 35617132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of latanoprost and latanoprostene bunod on intraocular pressure and pupil size in ophthalmologically normal Beagle dogs.
    Desai SJ; Pumphrey SA; Koethe B
    Vet Ophthalmol; 2022 Jul; 25(4):282-290. PubMed ID: 35247289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma.
    Einarson TR; Kulin NA; Tingey D; Iskedjian M
    Clin Ther; 2000 Dec; 22(12):1502-15. PubMed ID: 11192141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery.
    Berthold S; Pfeiffer N
    Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1029-34. PubMed ID: 16341541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Five years retrospective study of latanoprost glaucoma treatment].
    Závorková M; Susický P
    Cesk Slov Oftalmol; 2007 Jul; 63(4):292-8. PubMed ID: 17682609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.
    Feldman RM
    Expert Opin Pharmacother; 2004 Apr; 5(4):909-21. PubMed ID: 15102573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the use of latanoprost for glaucoma since its launch.
    Digiuni M; Fogagnolo P; Rossetti L
    Expert Opin Pharmacother; 2012 Apr; 13(5):723-45. PubMed ID: 22348427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.